IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GUTIERREZ-ARMENTA Atty. Ref.: 604-623

Serial No. To be assigned Group: 1638

Filed: December 26, 2001 Examiner: Mehta, A.

For: PLANT RETINOBLASTOMA-ASSOCIATED PROTEINS

December 26, 2001

Assistant Commissioner for Patents Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, before the first line, insert: This application is a continuation of Application No. 09/213,294, filed December 14, 1998, pending, which is a continuation of PCT/ES96/00130, filed June 13, 1996, abandoned, the entire content of which is hereby incorporated by reference in this application.

IN THE CLAIMS

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

* GUTIERREZ-ARMENTA Serial No. To be assigned

- 9 (Amended). Recombinant nucleic acid as claimed in claim 7 characterised in that it encodes for a retinoblastoma protein conservatively substituted with respect to SEQ ID No. 2.
- 12 (Amended). Recombinant nucleic acid as claimed in claim 10 characterised in that it comprises antisense DNA or RNA to that of SEQ ID No. 1 or a sequence having at least 80% homology thereto.
- 15 (Amended). A protein produced by the expression of a recombinant DNA or RNA as claimed in claim 7.
- 17 (Amended). A recombinant vector characterised in that it comprises a recombinant nucleic acid as claimed in claim 7.
- 19 (Amended). A plant cell as claimed in claim 18 characterised in that it cornorises a recombinant nucleic acid as defined above.
- 20 (Amended). A plant cell as claimed in claim 18 characterised in that it expresses a retinoblastoma protein from said nucleic acid.
- 21 (Amended). A transgenic plant characterised in that it comprises a cell as claimed in claim 18.

the time was the total that the iii. Ten Heart m

, GUTIERREZ-ARMENTA Serial No. To be assigned

REMARKS

The claims have been amended to remove the multiple dependencies. No new matter is entered.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page/s is/are captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Reg. No. 29,009

LCM:lks 1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

- 9 (Amended). Recombinant nucleic acid as claimed in claim 7 [or 8] characterised in that it encodes for a retinoblastoma protein conservatively substituted with respect to SEQ ID No. 2.
- 12 (Amended). Recombinant nucleic acid as claimed in claim 10 [or 11] characterised in that it comprises antisense DNA or RNA to that of SEQ ID No. 1 or a sequence having at least 80% homology thereto.
- 15 (Amended). A protein produced by the expression of a recombinant DNA or RNA as claimed in [any one of claims 7 to 9, 13 and 14] <u>claim 7</u>.
- 17 (Amended). A recombinant vector characterised in that it comprises a recombinant nucleic acid as claimed in [any one of claims 7 to 9, 13 and 14] <u>claim 7</u>.
- 19 (Amended). A plant cell as claimed in claim 18 characterised in that it cornorises a recombinant nucleic acid as [claimed in any one af claims 7 to 9, 13 and 14] <u>defined above</u>.
- 20 (Amended). A plant cell as claimed in claim 18 [or 19] characterised in that it expresses a retinoblastoma protein from said nucleic acid.
- 21 (Amended). A transgenic plant characterised in that it comprises a cell as claimed in [any one of claims 18 to 20] <u>claim 18</u>.